GLP-1 Agonist Therapy in a Patient With T2D and CVD

April 15, 2019 3:54 pm

Recommendations for initiating therapy with a GLP-1 receptor agonist in a 46-year-old woman with type 2 diabetes as well as hypertension and hypercholesterolemia, and insight regarding patient and physician misconceptions surrounding the prescribing and utilization of injectables.

Category: News
About The Author
-
Previous

[Preview] A low-carb diet for T2D reversal – Dr. Sarah Hallberg
Next

Mechanisms of Action of GLP-1 Agonists in T2D

Related Videos

Unleashing-the-Truth-How-to-Put-T2D-Patients-Hearts-First

Unleashing the Truth: How to Put T2D Patients’ Hearts First

logo_avatar

Insulin Treatment Is Associated with Increased Mortality in Patients with COVID-19 and Type 2 Diabetes

T2D-and-CV-Risk-Reduction-Future-Management

T2D and CV Risk Reduction: Future Management

Rogelio-Braceras-MD-Improving-Costs-Comorbidities-in-T2D

Rogelio Braceras, MD: Improving Costs, Comorbidities in T2D

Type-2-Diabetes-Treatments-1

A Data Integration Multi-Omics Approach to Study Calorie Restriction-Induced Changes in Insulin Sensitivity

Preview-A-low-carb-diet-for-T2D-reversal-Dr.-Sarah-Hallberg

[Preview] A low-carb diet for T2D reversal – Dr. Sarah Hallberg